Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
In this study, a single-arm, open-labeled clinical trial will be performed to determine the
safety and efficacy of EBV TCR-T cells in the treatment of recurrent/metastatic
nasopharyngeal carcinoma with positive EBV infection in the Chinese population.